<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985632</url>
  </required_header>
  <id_info>
    <org_study_id>CV006-030</org_study_id>
    <nct_id>NCT02985632</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants</brief_title>
  <official_title>Single-dose Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An oral dose of BMS-986141 administered in Hepatic Impairment and Healthy Participants to
      evaluate pharmacokinetics in this patient population.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business objectives have changed.
  </why_stopped>
  <start_date type="Anticipated">January 11, 2017</start_date>
  <completion_date type="Anticipated">July 7, 2017</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986141</measure>
    <time_frame>Days 1-7 (healthy) Days 1-10 (heaptic Impairment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986141</measure>
    <time_frame>Days 1-7 (healthy) Days 1-10 (heaptic Impairment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of BMS-986141</measure>
    <time_frame>Days 1-7 (healthy) Days 1-10 (heaptic Impairment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 144 hours postdose (AUC(0-144h)) of BMS-986141</measure>
    <time_frame>Days 1-7 (healthy) Days 1-10 (heaptic Impairment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), leading to discontinuation.</measure>
    <time_frame>Days 1-7 (healthy) Days 1-10 (heaptic Impairment)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects given an oral dose of BMS-986141.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects given an oral dose of BMS-986141.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects given an oral dose of BMS-986141.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986141</intervention_name>
    <arm_group_label>Mild Hepatic Impairment Subjects</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment Subjects</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women not of childbearing potential (WNOCBP), and males, ages 18 to 70 years,
             inclusive.

          -  BMI of 20.0 to 38.0 kg/m2 inclusive

          -  Participants who a history of normal renal function

          -  Subjects with hepatic impairment must be on a stable dose of medication and/or
             treatment regimen

          -  Healthy subjects to the extent possible matched to four subjects with hepatic
             impairment with regard to body weight, age and gender, as determined by no clinically
             significant deviation from normal in medical history, physical examination, ECGs, and
             clinical laboratory determinations

        Exclusion Criteria:

          -  Any nonhepatic significant acute or chronic medical illness that could affect
             participant safety or data interpretation as determined by the investigator.

          -  History of recurrent dizziness or fall risk within 4 weeks of study drug
             administration

          -  History of primarily cholestatic liver diseases, autoimmune liver disease, metastatic
             liver disease or active alcoholic hepatitis

          -  History of known bleeding diathesis or coagulation disorder (eg, thrombotic
             thrombocytopenic purpura)

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>BMS Clinical Trial Education Resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

